01—Abstract
Summary
Summary of the 10-Q filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. (DXCM) reported its first quarter 2025 financial results, showcasing continued revenue growth driven by increased sensor sales volume and a growing global customer base.
While revenue saw a healthy 12% year-over-year increase to $1.04 billiona, the company experienced a notable decrease in net income to $105.4 million from $146.4 million in the prior year. This decline was primarily attributed to a significant increase in income tax expense, partly due to shortfalls in share-based compensation, and increased cost of sales which compressed gross profit margins. The company ended the quarter with a strong liquidity position, holding $2.70 billion in cash, cash equivalents, and marketable securities.
Management highlighted strategic investments in R&D and product development, including the recent FDA clearance of the Dexcom G7 15 Day CGM System and the launch of the Stelo biosensor for prediabetes and Type 2 diabetes. Despite operational efficiencies in selling, general, and administrative expenses, driven by lower legal costs, investors should monitor the impact of increased cost of goods sold and rising tax expenses on future profitability.
02—Key points
Key Highlights
- Revenue increased by 12% year-over-year to $1.04 billion, primarily driven by higher sensor sales volume and customer growth.
- Net income decreased by 28% to $105.4 million, largely due to a significant increase in income tax expense.
- Gross profit margin contracted to 56.9% from 61.0% in the prior year, impacted by inefficiencies in supply availability, production yield, and product/channel mix.
- Selling, general, and administrative expenses decreased by 3% due to lower legal expenses related to a settled patent infringement lawsuit.
- The company maintained a strong liquidity position with $2.70 billion in cash, cash equivalents, and short-term marketable securities.
- Significant investments in research and development continue, supporting new product development and future growth initiatives.
- DexCom received FDA clearance for the G7 15 Day CGM System and launched the Stelo biosensor, expanding its market reach.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Dexcom Inc kept $0.10.
- Revenue$1.04B100.0%
- Cost of revenue−$447.0M43.1%
- Gross profit$589.0M56.9%
- Operating costs−$455.3M43.9%
- Operating income$133.7M12.9%
- Interest, other & tax−$28.3M2.7%
- Net income$105.4M10.2%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 1, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $1.04B$921.00M | +12.5% |
| Cost of Revenue | $447.00M$359.10M | +24.5% |
| Gross Profit | $589.00M$561.90M | +4.8% |
| R&D Expenses | $145.20M$141.50M | +2.6% |
| SG&A Expenses | $310.10M$319.30M | −2.9% |
| Operating Expenses | $455.30M$460.80M | −1.2% |
| Operating Income | $133.70M$101.10M | +32.2% |
| Interest Expense | $3.70M$3.70M | 0.0% |
| Net Income | $105.40M$146.40M | −28.0% |
| EPS (Basic) | $0.27$0.38 | −28.9% |
| EPS (Diluted) | $0.27$0.36 | −25.0% |
| Shares Outstanding (Basic) | 391.10M390.20M | +0.2% |
| Shares Outstanding (Diluted) | 407.50M416.70M | −2.2% |
05—Questions
Frequently Asked Questions
What was the primary driver of the revenue growth in Q1 2025?
Revenue growth of 12% to $1.04 billion was primarily driven by increased sales volume of disposable sensors due to the continued growth of Dexcom's worldwide customer base, adding approximately 500,000-600,000 net customers in 2024 (excluding Stelo customers).
Why did net income decrease despite revenue growth?
Net income decreased by 28% to $105.4 million primarily due to a significant increase in income tax expense for the quarter, which was impacted by shortfalls recognized for employee share-based compensation, net of disallowed executive compensation. Additionally, cost of sales increased at a higher rate than revenue, compressing gross profit margins.
What is the company's current liquidity position?
DexCom ended the first quarter of 2025 with a strong liquidity position, reporting $2.70 billion in cash, cash equivalents, and short-term marketable securities.
Are there any significant regulatory concerns mentioned in the filing?
Yes, DexCom received an FDA warning letter in March 2025 citing deficiencies in manufacturing processes and the quality management system. While this did not restrict current product sales or manufacturing, the company is actively responding and must resolve these issues to the FDA's satisfaction to avoid potential further regulatory actions.
06—Continue